Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vaxart, Inc.NASDAQ: VXRT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $29.41M fell 4.3% year over year, behind the +133.0% change in trailing-twelve-month research & development. Sequentially, it fell 34.9% from the prior quarter. Over 3 fiscal years it compounded at +35.5% a year.
Context
- Research & development amounted to 85.0% of revenue in FY2025, down 173.6 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -4.3% toward the trailing-twelve-month pace of +133.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 201.58M USD
- Year-over-year change
- +171.6%
- 4-year CAGR
- +42.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 201.58M | +171.6% |
| FY2024 | 2024-12-31 | 74.21M | +8.9% |
| FY2023 | 2023-12-31 | 68.14M | -15.9% |
| FY2022 | 2022-12-31 | 81.05M | +66.3% |
| FY2021 | 2021-12-31 | 48.75M | — |
Research & Development vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's LTM Mar 2026 research & development of $200.25M is the highest of the 10 companies compared; the peer median is $41.12M.
- Its year-over-year change of +133.0% is the highest of 10, against a peer median of -11.8%.
- Research & development amounts to 78.3% of revenue for VXRT, versus a peer median of 958.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $200.25M | +133.0% | +35.5% | 78.3% | |
| LTM Mar 2026 | $106.27M | -5.4% | +24.0% | 1163.2% | |
| LTM Mar 2026 | $86.08M | +3.9% | +4.8% | — | |
| LTM Mar 2026 | $67.7M | +8.5% | +10.6% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59.66M | -11.8% | +35.8% | — |
CBUSCibus, Inc. | LTM Mar 2026 | $41.12M | -18.1% | +56.4% | 959.3% |
| LTM Mar 2026 | $37.7M | -3.9% | — | 958.2% | |
| LTM Mar 2026 | $23.02M | -48.6% | -81.3% | — | |
| LTM Mar 2026 | $8.57M | -44.2% | -9.8% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| Peer median (excluding VXRT) | $41.12M | -11.8% | +7.7% | 958.8% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 892K | 107K | 7.38M | 28.7M | 237.26M |
| Cost of Revenue | 48.75M | 0 | 4.5M | 0 | 0 |
| Gross Profit | (47.86M) | 107K | 2.88M | 28.7M | 237.26M |
| Gross Margin | -5365.1% | 100.0% | 39.0% | 100.0% | 100.0% |
| Research & Development | 48.75M | 81.05M | 68.14M | 74.21M | 201.58M |
| Selling, General & Admin | 21.89M | 29.39M | 22.58M | 20.78M | 17.61M |
| Operating Expenses | 24.9M | 114.69M | 86.23M | 94.99M | 219.18M |
| Depreciation & Amortization | 2.43M | 5.81M | 8.62M | 8.85M | 8.58M |
| EBITDA | (66.45M) | (100.58M) | (72.13M) | (54.87M) | 28.21M |
| EBITDA Margin | -7449.7% | -94000.9% | -977.5% | -191.2% | 11.9% |
| Operating Income | (72.75M) | (114.59M) | (83.35M) | (66.29M) | 18.07M |
| Operating Margin | -8156.1% | -107090.7% | -1129.5% | -231.0% | 7.6% |
| Interest Income | 81K | 1.25M | 2.65M | 2.54M | 1.6M |
| Interest Expense | 1.48M | 1.31M | 1.45M | 2.97M | 2.82M |
| Other Income / Expenses | 2.39M | 6.9M | 1.14M | (395K) | (1.27M) |
| Income Before Tax | (70.36M) | (107.69M) | (82.2M) | (66.69M) | 16.8M |
| Pre-Tax Margin | -7888.2% | -100645.8% | -1114.0% | -232.4% | 7.1% |
| Income Tax Expense | 107K | 67K | 261K | 260K | 476K |
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Net Margin | -7900.2% | -100708.4% | -1117.6% | -233.3% | 6.9% |
| EPS (Basic) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| EPS (Diluted) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| Weighted Avg Shares | 487.26M | 487.26M | 487.26M | 487.26M | 230.27M |
| Weighted Avg Shares (Diluted) | 487.26M | 487.26M | 487.26M | 487.26M | 230.35M |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.